Reports >
Life Sciences
>
Migraine Therapeutics Market Report
Migraine Therapeutics Market Size, Share, Industry Trends and Forecast to 2033
This report provides a comprehensive analysis of the Migraine Therapeutics market, offering insights into market trends, size, segmentation, and regional dynamics from 2023 to 2033.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $8.50 Billion |
| CAGR (2023-2033) | 6.2% |
| 2033 Market Size | $15.75 Billion |
| Top Companies | Amgen Inc., Eli Lilly and Company, Teva Pharmaceutical Industries, Pfizer Inc., AbbVie |
| Last Modified Date | 15 Nov 2024 |
Migraine Therapeutics Market Report (2023 - 2033)
Migraine Therapeutics Market Overview
What is the Market Size & CAGR of Migraine Therapeutics market in 2023?
Migraine Therapeutics Industry Analysis
Migraine Therapeutics Market Segmentation and Scope
Request a custom research report for industry.
Migraine Therapeutics Market Analysis Report by Region
Europe Migraine Therapeutics Market Report:
The European market is anticipated to grow from $2.28 billion in 2023 to $4.22 billion by 2033, supported by robust healthcare frameworks and increasing availability of innovative therapeutic options.Asia Pacific Migraine Therapeutics Market Report:
In the Asia Pacific region, the market is expected to grow from $1.65 billion in 2023 to $3.05 billion by 2033, driven by increased awareness of migraine treatment and improved access to healthcare services.North America Migraine Therapeutics Market Report:
North America holds a significant share in the market, projected to increase from $3.28 billion in 2023 to $6.08 billion by 2033, primarily due to advanced healthcare infrastructure and a high incidence rate of migraine disorders.South America Migraine Therapeutics Market Report:
The South American market exhibits growth potential, expanding from $0.82 billion in 2023 to $1.52 billion in 2033, fueled by rising healthcare investments and a growing focus on chronic pain management.Middle East & Africa Migraine Therapeutics Market Report:
In the Middle East and Africa, the market is expected to rise from $0.47 billion in 2023 to $0.87 billion by 2033, as healthcare access improves and awareness about migraine treatments increases.Request a custom research report for industry.
Migraine Therapeutics Market Analysis By Drug Type
Global Migraine Therapeutics Market, By Drug Type Market Analysis (2023 - 2033)
In the Migraine Therapeutics market, acute medications dominate the landscape with a size of $6.94 billion in 2023 and expected growth to $12.85 billion by 2033, maintaining an 81.61% market share. Preventive medications account for $1.56 billion in 2023, growing to $2.90 billion by 2033, representing 18.39% of the market.
Migraine Therapeutics Market Analysis By Route Of Administration
Global Migraine Therapeutics Market, By Route of Administration Market Analysis (2023 - 2033)
Oral medications are significant, comprising $5.35 billion in 2023 with projections to grow to $9.91 billion by 2033, holding a 62.91% share. Injectable and nasal routes follow closely with sizes of $2.10 billion and $1.05 billion in 2023, respectively.
Migraine Therapeutics Market Analysis By Patient Type
Global Migraine Therapeutics Market, By Patient Type Market Analysis (2023 - 2033)
The adult demographic dominates the patient market with a size of $5.35 billion in 2023, expected to rise to $9.91 billion by 2033. Children and pregnant women also represent critical segments, yielding $2.10 billion and $1.05 billion respectively in 2023.
Migraine Therapeutics Market Analysis By Therapy Type
Global Migraine Therapeutics Market, By Therapy Type Market Analysis (2023 - 2033)
Pharmacological therapy leads the market at $6.94 billion in 2023, expected to expand to $12.85 billion by 2033, while non-pharmacological therapy accounts for $1.56 billion in 2023, forecasted to reach $2.90 billion.
Migraine Therapeutics Market Analysis By Distribution Channel
Global Migraine Therapeutics Market, By Distribution Channel Market Analysis (2023 - 2033)
Hospital pharmacies command the largest market share at $5.35 billion in 2023, projected to increase to $9.91 billion. Retail and online pharmacies account for $2.10 billion and $1.05 billion respectively in 2023.
Migraine Therapeutics Market Trends and Future Forecast
Request a custom research report for industry.
Global Market Leaders and Top Companies in Migraine Therapeutics Industry
Amgen Inc.:
Amgen is known for its innovative treatments, including migraine therapies like Aimovig, which target the CGRP receptor.Eli Lilly and Company:
Eli Lilly produces Emgality, a preventative migraine medication that has gained significant market traction.Teva Pharmaceutical Industries:
Teva brings a diverse portfolio of migraine treatments, including the generic formulations and branded medications.Pfizer Inc.:
Pfizer is involved in the migraine therapy landscape with variations in their product offerings for pain relief.AbbVie:
AbbVie has entered the migraine therapeutics space with products focusing on new pharmacological innovations.We're grateful to work with incredible clients.
